#ECTRIMS2021 – ATA188 Benefits in SPMS, PPMS Hint at Remyelination
An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study.
EMBOLD trial findings based on MRI brain imaging data measuring the magnetization transfer ratio (MTR) also suggest gains in these ATA188-treated patients may be tied to remyelination, or the regrowth of the myelin sheath, the fatty material surrounding nerve fibers that is damaged in MS.
Trial results extending out to 39 months, including MTR data, will be presented as an e-poster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place virtually Oct. 13–15, Atara reported in a press release,
#ECTRIMS2021 - ATA188 Benefits in SPMS, PPMS Hint at Remyelination (multiplesclerosisnewstoday.com)
An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study.
EMBOLD trial findings based on MRI brain imaging data measuring the magnetization transfer ratio (MTR) also suggest gains in these ATA188-treated patients may be tied to remyelination, or the regrowth of the myelin sheath, the fatty material surrounding nerve fibers that is damaged in MS.
Trial results extending out to 39 months, including MTR data, will be presented as an e-poster at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place virtually Oct. 13–15, Atara reported in a press release,
#ECTRIMS2021 - ATA188 Benefits in SPMS, PPMS Hint at Remyelination (multiplesclerosisnewstoday.com)
Comment